Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium
Primary Purpose
Hand, Foot and Mouth Disease
Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
suramin sodium
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Hand, Foot and Mouth Disease focused on measuring suramin sodium
Eligibility Criteria
Inclusion Criteria:
- Healthy volunteers who fully understand the purpose, content, benefits and possible adverse reactions of the test and voluntarily sign written informed consent prior to the commencement of any test-related activities.
- Healthy males or females, aged 18 to 45 years (including 18 and 45 years).
- Male subjects weighed 50-75 kg (including 50 and 75 kg), female subjects weighed 45-75 kg (including 45 and 75 kg), body mass index (BMI) was 18.0-26.0 kg/m2 (including 18.0 and 26.0 kg/m2), where BMI = body weight (kg)/height2 (m2).
- Have the ability to communicate with investigator and abide by the management regulations of the hospital and the clinical research.
Exclusion Criteria:
- Fail in physical examination, vital signs measurement, standard 12-lead electrocardiogram, chest X-ray, laboratory examination [blood routine, urine routine, blood biochemistry, blood coagulation function, infectious diseases, blood pregnancy (only for women of childbearing age), as judged by the investigator to be of clinical significance.
- With gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immunity, mental or cardiovascular diseases.
- Has allergic constitution (allergic to two or more substances), or allergic history, or known allergic to suramin sodium.
- Cannot tolerate venipuncture and/or have a history of fainting blood or needle.
- Has massive blood loss (> 400 mL) or had donated blood/blood components within the first six months of screening, or who planned to donate blood/blood components during the study period.
- Had participated in clinical trials of drugs and took research drugs within three months before screening.
- Smoke more than five cigarettes a day (including nicotine substitutes) or the same amount of tobacco products in the first three months of screening.
- Has history of drug abuse within 5 years before screening, or those who had used drugs within 3 months before screening.
- Has a history of alcoholism or moderate alcoholism in the first two years of screening (moderate alcoholism is defined as drinking more than 3 units per day or 21 units per week; a bottle of 350 mL beer, 120 mL white wine, 150 mL wine or 30 mL spirits is one unit).
- Pregnant or lactating women, or subjects (or their partners) who have pregnancy plans during the trial and within three months after the end of the study, or who do not agree to use non-drug contraceptive measures during the trial.
- Positive urine drug screening in screening stage.
- Alcohol urine positive in screening stage.
- Nicotine positive in screening stage.
- With acute diseases in screening period.
- Had used any prescription, over-the-counter, vitamin products or Chinese herbal medicines within 14 days before enrollment.
- Female subjects of childbearing age who did not take non-drug contraceptive measures within 14 days before admission.
- Not suitable for participating into the trial as judged by the investigator.
Sites / Locations
- First Affiliated Hospital of Zhejiang UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Arm Label
Group 1-1
Group 1-2
Group 2-1
Group 2-2
Group 3-1
Group 3-2
Arm Description
The dose of suramin sodium is 10 mg/kg
The placebo is 0.9% sodium chloride injection
The dose of suramin sodium is 15mg/kg
The placebo is 0.9% sodium chloride injection
The dose of suramin sodium is 20mg/kg
The placebo is 0.9% sodium chloride injection
Outcomes
Primary Outcome Measures
Number of subjects with adverse events
Adverse events
the area under the plasma concentration-time curve (AUC) from time zero to the time of the last measurable concentration (AUC0-t) of suramin sodium
Pharmacokinetics parameters
the AUC from time zero to infinity (AUC0-inf) of suramin sodium
Pharmacokinetics parameters
maximum plasma concentration (Cmax ) of suramin sodium
Pharmacokinetics parameters
half life (t1/2) of suramin sodium
Pharmacokinetics parameters
clearance (CL) of suramin sodium
Pharmacokinetics parameters
apparent volume of distribution(Vd) of suramin sodium
Pharmacokinetics parameters
the amount of drug excreted into the urine from time zero to time 7 days(Ae0-t) of suramin sodium
Pharmacokinetics parameters
Secondary Outcome Measures
Full Information
NCT ID
NCT03804749
First Posted
December 28, 2018
Last Updated
January 11, 2019
Sponsor
First Affiliated Hospital of Zhejiang University
Collaborators
Guangdong Kangda Pharmaceutical Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT03804749
Brief Title
Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium
Official Title
A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Unknown status
Study Start Date
December 19, 2018 (Actual)
Primary Completion Date
December 19, 2019 (Anticipated)
Study Completion Date
December 19, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
First Affiliated Hospital of Zhejiang University
Collaborators
Guangdong Kangda Pharmaceutical Co., Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a randomized, double-blind, placebo-controlled, single-dose with three incremental doses, Phase 1 study to evaluate the tolerance and pharmacokinetics of suramin sodium for injection in Chinese healthy adults.
Detailed Description
A total of 36 subjects are divided into three dosage groups: 10mg/kg, 15mg/kg and 20mg/kg, in which 20mg/kg is the conventional dosage per international pharmacopoeias for established indications of suramin sodium. Each dose group contains 12 subjects. By randomization, 10 of them receive suramin sodium while 2 of them receive placebo (0.9% sodium chloride injection). The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.
All subjects in each dose group will be un-blinded after blood/urine collection and safety evaluation on Day 28. After that, blood and urine samples on suramin-dosing subjects will continue to collect on Days 56、84、112 and 140.
Subjects receiving placebo will complete the study on Day 28 if no AE is observed, or follow up till the adverse event (AE) return to normal or stabilize if AE is detected.
Blood and urine samples will be tested by a validated LC/MS method for pharmacokinetic study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand, Foot and Mouth Disease
Keywords
suramin sodium
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
Double blind, placebo control
Allocation
Randomized
Enrollment
36 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group 1-1
Arm Type
Experimental
Arm Description
The dose of suramin sodium is 10 mg/kg
Arm Title
Group 1-2
Arm Type
Placebo Comparator
Arm Description
The placebo is 0.9% sodium chloride injection
Arm Title
Group 2-1
Arm Type
Experimental
Arm Description
The dose of suramin sodium is 15mg/kg
Arm Title
Group 2-2
Arm Type
Placebo Comparator
Arm Description
The placebo is 0.9% sodium chloride injection
Arm Title
Group 3-1
Arm Type
Experimental
Arm Description
The dose of suramin sodium is 20mg/kg
Arm Title
Group 3-2
Arm Type
Placebo Comparator
Arm Description
The placebo is 0.9% sodium chloride injection
Intervention Type
Drug
Intervention Name(s)
suramin sodium
Intervention Description
The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
Intervention Type
Other
Intervention Name(s)
placebo
Other Intervention Name(s)
0.9% sodium chloride injection
Intervention Description
Placebo is 0.9% sodium chloride injection.
Primary Outcome Measure Information:
Title
Number of subjects with adverse events
Description
Adverse events
Time Frame
[ Day 1 to Day 140 ]
Title
the area under the plasma concentration-time curve (AUC) from time zero to the time of the last measurable concentration (AUC0-t) of suramin sodium
Description
Pharmacokinetics parameters
Time Frame
[ Day 1 to Day 140 after study drug administration ]
Title
the AUC from time zero to infinity (AUC0-inf) of suramin sodium
Description
Pharmacokinetics parameters
Time Frame
[ Day 1 to Day 140 after study drug administration ]
Title
maximum plasma concentration (Cmax ) of suramin sodium
Description
Pharmacokinetics parameters
Time Frame
[ Day 1 to Day 140 after study drug administration ]
Title
half life (t1/2) of suramin sodium
Description
Pharmacokinetics parameters
Time Frame
[Day 1 to Day 140 after study drug administration ]
Title
clearance (CL) of suramin sodium
Description
Pharmacokinetics parameters
Time Frame
[ Day 1 to Day 140 after study drug administration ]
Title
apparent volume of distribution(Vd) of suramin sodium
Description
Pharmacokinetics parameters
Time Frame
[ Day 1 to Day 140 after study drug administration ]
Title
the amount of drug excreted into the urine from time zero to time 7 days(Ae0-t) of suramin sodium
Description
Pharmacokinetics parameters
Time Frame
[ Day 1 to Day 7 after study drug administration ]
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy volunteers who fully understand the purpose, content, benefits and possible adverse reactions of the test and voluntarily sign written informed consent prior to the commencement of any test-related activities.
Healthy males or females, aged 18 to 45 years (including 18 and 45 years).
Male subjects weighed 50-75 kg (including 50 and 75 kg), female subjects weighed 45-75 kg (including 45 and 75 kg), body mass index (BMI) was 18.0-26.0 kg/m2 (including 18.0 and 26.0 kg/m2), where BMI = body weight (kg)/height2 (m2).
Have the ability to communicate with investigator and abide by the management regulations of the hospital and the clinical research.
Exclusion Criteria:
Fail in physical examination, vital signs measurement, standard 12-lead electrocardiogram, chest X-ray, laboratory examination [blood routine, urine routine, blood biochemistry, blood coagulation function, infectious diseases, blood pregnancy (only for women of childbearing age), as judged by the investigator to be of clinical significance.
With gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immunity, mental or cardiovascular diseases.
Has allergic constitution (allergic to two or more substances), or allergic history, or known allergic to suramin sodium.
Cannot tolerate venipuncture and/or have a history of fainting blood or needle.
Has massive blood loss (> 400 mL) or had donated blood/blood components within the first six months of screening, or who planned to donate blood/blood components during the study period.
Had participated in clinical trials of drugs and took research drugs within three months before screening.
Smoke more than five cigarettes a day (including nicotine substitutes) or the same amount of tobacco products in the first three months of screening.
Has history of drug abuse within 5 years before screening, or those who had used drugs within 3 months before screening.
Has a history of alcoholism or moderate alcoholism in the first two years of screening (moderate alcoholism is defined as drinking more than 3 units per day or 21 units per week; a bottle of 350 mL beer, 120 mL white wine, 150 mL wine or 30 mL spirits is one unit).
Pregnant or lactating women, or subjects (or their partners) who have pregnancy plans during the trial and within three months after the end of the study, or who do not agree to use non-drug contraceptive measures during the trial.
Positive urine drug screening in screening stage.
Alcohol urine positive in screening stage.
Nicotine positive in screening stage.
With acute diseases in screening period.
Had used any prescription, over-the-counter, vitamin products or Chinese herbal medicines within 14 days before enrollment.
Female subjects of childbearing age who did not take non-drug contraceptive measures within 14 days before admission.
Not suitable for participating into the trial as judged by the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jianzhong Shentu, Ph.D.(Pharm)
Phone
0571 87236560
Email
stjz@zju.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
First Affiliated Hospital Zhejiang University
Organizational Affiliation
First Affiliated Hospital of Zhejiang University
Official's Role
Principal Investigator
Facility Information:
Facility Name
First Affiliated Hospital of Zhejiang University
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianzhong Shentu, Ph.D.(Pharm)
Phone
0571 87236560
Email
stjz@zju.edu.cn
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium
We'll reach out to this number within 24 hrs